Cargando…
Severe steroid refractory gastritis induced by Nivolumab: A case report
BACKGROUND: Immune checkpoint inhibitors are widely used for treatment of many advanced malignancies. Lower gastrointestinal (GI) side effects, such as diarrhea and colitis, are common, but upper GI side effects are rarely reported. Consequently, the correct treatment of upper GI adverse events has...
Autores principales: | Vindum, Helene Hjorth, Agnholt, Jørgen S, Nielsen, Anders Winther Moelby, Nielsen, Mette Bak, Schmidt, Henrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201147/ https://www.ncbi.nlm.nih.gov/pubmed/32390707 http://dx.doi.org/10.3748/wjg.v26.i16.1971 |
Ejemplares similares
-
Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018) -
Severe Esophagitis and Gastritis from Nivolumab Therapy
por: Boike, Justin, et al.
Publicado: (2017) -
Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
por: Samonis, George, et al.
Publicado: (2022) -
Nivolumab-induced tumour-like gastritis: A case report
por: Cijauskaite, Elena, et al.
Publicado: (2023) -
Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report
por: Nassri, Ammar B, et al.
Publicado: (2019)